Contrasting Marathon Patent Group (MARA) and Stericycle (SRCL)
Marathon Patent Group (NASDAQ: MARA) and Stericycle (NASDAQ:SRCL) are both finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
This table compares Marathon Patent Group and Stericycle’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Marathon Patent Group||-5,770.02%||-1,139.06%||-175.07%|
This is a summary of current ratings and price targets for Marathon Patent Group and Stericycle, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Marathon Patent Group||0||0||1||0||3.00|
Marathon Patent Group presently has a consensus target price of $3.00, suggesting a potential upside of 711.03%. Stericycle has a consensus target price of $80.91, suggesting a potential upside of 12.09%. Given Marathon Patent Group’s stronger consensus rating and higher probable upside, research analysts plainly believe Marathon Patent Group is more favorable than Stericycle.
Insider and Institutional Ownership
8.4% of Marathon Patent Group shares are held by institutional investors. Comparatively, 93.7% of Stericycle shares are held by institutional investors. 19.8% of Marathon Patent Group shares are held by insiders. Comparatively, 3.3% of Stericycle shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Marathon Patent Group has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Stericycle has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500.
Earnings and Valuation
This table compares Marathon Patent Group and Stericycle’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Marathon Patent Group||$666,774.00||13.46||-$10.40 million||($2.45)||-0.15|
|Stericycle||$3.61 billion||1.71||$777.58 million||($0.26)||-277.62|
Stericycle has higher revenue and earnings than Marathon Patent Group. Stericycle is trading at a lower price-to-earnings ratio than Marathon Patent Group, indicating that it is currently the more affordable of the two stocks.
Stericycle beats Marathon Patent Group on 8 of the 13 factors compared between the two stocks.
About Marathon Patent Group
Marathon Patent Group Inc. (MARA) is engaged in acquiring patents and patent rights from owners or other ventures. The Company monetizes its portfolio of patents and patent rights by entering into license discussions. The Company owns around 378 United States and foreign patents, and patent rights across a range of technologies and markets. The Company owns around 22 patent applications across a range of technologies and markets.
Stericycle, Inc. is a business-to-business services provider. The Company focuses on regulated and compliance solutions for healthcare, retail, and commercial businesses. The Company’s segments include Domestic and Canada Regulated Waste and Compliance Services (RCS), Domestic Communication and Related Services (CRS), International RCS and All other. The Domestic and Canada RCS and International RCS segments include medical waste disposal, pharmaceutical waste disposal, hazardous waste management, sustainability solutions for expired or unused inventory, secure information destruction of documents and e-media, training and consulting through its Steri-Safe and Clinical Services programs, and other regulatory compliance services. The Domestic CRS segment consists of inbound/outbound communication, automated patient reminders, online scheduling, notifications, product retrievals, product returns and quality audits.
Receive News & Ratings for Marathon Patent Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marathon Patent Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.